\-\ Texto\\:\\ \ \(0\)\
\-\ neurological\\ exam\\ was\\ significant\\ for\\ a\\ right\\ sided\\ central\\ facial\\ weakness\\ and\\ mild\\ right\\ sided\\ weakness\\ with\\ a\\ 4\\-5\\ beat\\ clonus\\.\\ some\\ difficulty\\ with\\ tandem\\ gait\\ and\\ decrease\\ in\\ right\\ arm\\ swing\\ was\\ observed\\ on\\ natural\\ gait\\.\ \(0\)\
\-\ the\\ patient\\ was\\ treated\\ initially\\ with\\ solumedrol\\,\\ and\\ then\\ switched\\ to\\ prednisone\\,\\ and\\ then\\ to\\ a\\ lower\\ dose\\ prednisone\\ and\\ imuran\\.\\ the\\ patient\\'s\\ disease\\ showed\\ good\\ response\\ to\\ the\\ steroids\\ and\\ immunosuppression\\.\ \(0\)\
\-\ serial\\ mri\\ was\\ done\\ to\\ follow\\ the\\ lesions\\,\\ which\\ also\\ showed\\ good\\ response\\ to\\ steroids\\.\ \(0\)\
\-\ mri\\ evaluation\\ was\\ significant\\ for\\:\ \(0\)\
\-\ \\â\\€\\¢\\ lesion\\ in\\ the\\ left\\ midbrain\\ with\\ t1\\ and\\ t2\\ signal\\ hyperintensity\\ that\\ enhances\\ with\\ contrast\\,\\ with\\ a\\ surrounding\\ area\\ of\\ t2\\ hyperintensity\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ lesions\\ in\\ the\\ pons\\,\\ thalamus\\,\\ and\\ medulla\\ found\\ in\\ the\\ white\\ matter\\ \\-\\ with\\ no\\ significant\\ mass\\ effect\\.\ \(1\)\
\-\ behcet\\ disease\\/syndrome\ \(0\)\
\-\ \\â\\€\\¢\\ adem\ \(0\)\
\-\ \\â\\€\\¢\\ inflammatory\\ disorders\\ including\\ behcet\\'s\ \(0\)\
\-\ \\â\\€\\¢\\ cerebritis\ \(1\)\
\-\ \\â\\€\\¢\\ rhombencephalitis\ \(1\)\
\-\ \\â\\€\\¢\\ cerebral\\ infarcts\ \(1\)\
\-\ a\\ 24\\ yo\\ right\\-hand\\ dominant\\ man\\ presented\\ with\\ a\\ 4\\ wk\\ course\\ of\\ insidious\\ onset\\ right\\ sided\\ weakness\\ including\\ facial\\ weakness\\ and\\ mild\\ dysarthria\\.\ \(0\)\
\-\ the\\ patient\\'s\\ initial\\ presentation\\ of\\ right\\ sided\\ weakness\\ can\\ be\\ explained\\ by\\ the\\ lesions\\ seen\\ on\\ mri\\.\\ however\\,\\ without\\ any\\ histological\\ specimens\\,\\ it\\ was\\ difficult\\ to\\ determine\\ the\\ exact\\ etiology\\ of\\ the\\ lesion\\.\\ \ \(0\)\
\-\ csf\\ analysis\\ pointed\\ in\\ the\\ direction\\ that\\ the\\ etiology\\ was\\ most\\ likely\\ to\\ be\\ inflammatory\\,\\ and\\ not\\ infectious\\,\\ and\\ the\\ trial\\ of\\ immunosuppression\\ proved\\ to\\ be\\ successful\\ clinically\\ as\\ well\\ as\\ radiographically\\.\\ \ \(0\)\
\-\ it\\ was\\ not\\ until\\ an\\ exacerbation\\ of\\ the\\ disease\\,\\ when\\ the\\ patient\\ presented\\ with\\ the\\ oral\\ and\\ genital\\ lesions\\,\\ that\\ the\\ clinical\\ diagnosis\\ of\\ behcet\\'s\\ disease\\ was\\ made\\.\ \(0\)\
\-\ the\\ diagnosis\\ led\\ to\\ a\\ further\\ advance\\ in\\ the\\ treatment\\ to\\ lower\\ the\\ steroid\\ dose\\ and\\ augment\\ with\\ imuran\\.\\ \ \(0\)\
\-\ radiographic\\ follow\\-up\\ of\\ the\\ lesions\\ proves\\ paramount\\ to\\ fine\\ tune\\ the\\ effective\\ dosages\\ of\\ the\\ medications\\,\\ thereby\\ preventing\\ the\\ patient\\ from\\ being\\ subjected\\ to\\ subtherapeutic\\ dosages\\ and\\ therefore\\ symptomatic\\.\ \(0\)\
\-\ this\\ case\\ is\\ a\\ good\\ example\\ of\\ a\\ combined\\ radiographic\\ and\\ clinical\\ diagnosis\\,\\ as\\ well\\ the\\ value\\ of\\ imaging\\ follow\\-up\\ \\-\\ playing\\ a\\ key\\ role\\ in\\ monitoring\\ the\\ course\\ of\\ treatment\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ the\\:\\ 0\\.2979431698621285\ \(0\)\
\-\ behcet\\:\\ 0\\.2215787522109846\ \(0\)\
\-\ weakness\\:\\ 0\\.20180672062142194\ \(0\)\
\-\ was\\:\\ 0\\.17346247018698696\ \(0\)\
\-\ and\\:\\ 0\\.17141500486864203\ \(0\)\
\-\ imuran\\:\\ 0\\.16902091042820439\ \(0\)\
\-\ dosages\\:\\ 0\\.16902091042820439\ \(0\)\
\-\ to\\:\\ 0\\.16590739318660774\ \(0\)\
\-\ lesions\\:\\ 0\\.1588054109521371\ \(0\)\
\-\ immunosuppression\\:\\ 0\\.15000294367937636\ \(0\)\
\-\ sided\\:\\ 0\\.1422945729451471\ \(0\)\
\-\ good\\:\\ 0\\.13493813758474205\ \(0\)\
\-\ of\\:\\ 0\\.12987039044015858\ \(0\)\
\-\ prednisone\\:\\ 0\\.11651267974424132\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.11029883178899826\ \(0\)\
\-\ right\\:\\ 0\\.11001119517742536\ \(0\)\
\-\ with\\:\\ 0\\.1082899899729168\ \(0\)\
\-\ dose\\:\\ 0\\.10328942347118635\ \(0\)\
\-\ response\\:\\ 0\\.10202443053611673\ \(0\)\
\-\ steroids\\:\\ 0\\.09717421509639142\ \(0\)\
\-\ in\\:\\ 0\\.09630296511555375\ \(0\)\
\-\ gait\\:\\ 0\\.09579412973183757\ \(0\)\
\-\ significant\\:\\ 0\\.09579202669633569\ \(0\)\
\-\ disease\\:\\ 0\\.09285676926660782\ \(0\)\
\-\ facial\\:\\ 0\\.09120283804784972\ \(0\)\
\-\ patient\\:\\ 0\\.08993628375426575\ \(0\)\
\-\ follow\\:\\ 0\\.08943919453462652\ \(0\)\
\-\ etiology\\:\\ 0\\.08910161633909428\ \(0\)\
\-\ augment\\:\\ 0\\.0884413748518135\ \(0\)\
\-\ tune\\:\\ 0\\.0884413748518135\ \(0\)\
\-\ diagnosis\\:\\ 0\\.08600589248135801\ \(0\)\
\-\ mri\\:\\ 0\\.08516280382342926\ \(0\)\
\-\ swing\\:\\ 0\\.08451045521410219\ \(0\)\
\-\ rhombencephalitis\\:\\ 0\\.08451045521410219\ \(0\)\
\-\ subtherapeutic\\:\\ 0\\.08451045521410219\ \(0\)\
\-\ radiographic\\:\\ 0\\.08206043804733962\ \(0\)\
\-\ solumedrol\\:\\ 0\\.08172142334575083\ \(0\)\
\-\ course\\:\\ 0\\.08169935347041457\ \(0\)\
\-\ including\\:\\ 0\\.07915499185233703\ \(0\)\
\-\ then\\:\\ 0\\.07829581478046103\ \(0\)\
\-\ pointed\\:\\ 0\\.07779050370803953\ \(0\)\
\-\ subjected\\:\\ 0\\.07779050370803953\ \(0\)\
\-\ proves\\:\\ 0\\.07629603742134275\ \(0\)\
\-\ paramount\\:\\ 0\\.07629603742134275\ \(0\)\
\-\ inflammatory\\:\\ 0\\.07479069611934616\ \(0\)\
\-\ wk\\:\\ 0\\.07385958407032821\ \(0\)\
\-\ showed\\:\\ 0\\.07367128198272722\ \(0\)\
\-\ advance\\:\\ 0\\.07283813065360596\ \(0\)\
\-\ thereby\\:\\ 0\\.07283813065360596\ \(0\)\
\-\ that\\:\\ 0\\.07199815256152771\ \(0\)\
\-\ beat\\:\\ 0\\.07191411364209367\ \(0\)\
\-\ tandem\\:\\ 0\\.07191411364209367\ \(0\)\
\-\ switched\\:\\ 0\\.07191411364209367\ \(0\)\
\-\ genital\\:\\ 0\\.07107055220197686\ \(0\)\
\-\ clinical\\:\\ 0\\.07009675515441888\ \(0\)\
\-\ clonus\\:\\ 0\\.06769377428184077\ \(0\)\
\-\ be\\:\\ 0\\.06730252560888814\ \(0\)\
\-\ specimens\\:\\ 0\\.06713963256426554\ \(0\)\
\-\ as\\:\\ 0\\.0666514116530236\ \(0\)\
\-\ dysarthria\\:\\ 0\\.06661545946626592\ \(0\)\
\-\ insidious\\:\\ 0\\.0661181791475433\ \(0\)\
\-\ cerebritis\\:\\ 0\\.06564516627756875\ \(0\)\
\-\ preventing\\:\\ 0\\.06564516627756875\ \(0\)\
\-\ explained\\:\\ 0\\.06519416213603099\ \(0\)\
\-\ presented\\:\\ 0\\.06449903639178008\ \(0\)\
\-\ natural\\:\\ 0\\.0643506006959142\ \(0\)\
\-\ thalamus\\:\\ 0\\.06395483796146108\ \(0\)\
\-\ medulla\\:\\ 0\\.06395483796146108\ \(0\)\
\-\ t2\\:\\ 0\\.06363456864594076\ \(0\)\
\-\ proved\\:\\ 0\\.06357459939479716\ \(0\)\
\-\ mild\\:\\ 0\\.06269928213718598\ \(0\)\
\-\ midbrain\\:\\ 0\\.06156156882756284\ \(0\)\
\-\ trial\\:\\ 0\\.06156156882756284\ \(0\)\
\-\ histological\\:\\ 0\\.060973822775778105\ \(0\)\
\-\ direction\\:\\ 0\\.060973822775778105\ \(0\)\
\-\ exact\\:\\ 0\\.06069279322313519\ \(0\)\
\-\ exacerbation\\:\\ 0\\.06069279322313519\ \(0\)\
\-\ led\\:\\ 0\\.05964367975708585\ \(0\)\
\-\ adem\\:\\ 0\\.05939822764148063\ \(0\)\
\-\ key\\:\\ 0\\.05825633987212066\ \(0\)\
\-\ role\\:\\ 0\\.058043257872440406\ \(0\)\
\-\ pons\\:\\ 0\\.056854647888734504\ \(0\)\
\-\ it\\:\\ 0\\.056617561994248486\ \(0\)\
\-\ lower\\:\\ 0\\.056519683535896474\ \(0\)\
\-\ effective\\:\\ 0\\.056488761420491564\ \(0\)\
\-\ fine\\:\\ 0\\.056310869443886115\ \(0\)\
\-\ value\\:\\ 0\\.056310869443886115\ \(0\)\
\-\ radiographically\\:\\ 0\\.05514941589449913\ \(0\)\
\-\ example\\:\\ 0\\.05514941589449913\ \(0\)\
\-\ monitoring\\:\\ 0\\.05514941589449913\ \(0\)\
\-\ combined\\:\\ 0\\.054841617321500176\ \(0\)\
\-\ infarcts\\:\\ 0\\.054112338234729086\ \(0\)\
\-\ successful\\:\\ 0\\.05369972955214022\ \(0\)\
\-\ playing\\:\\ 0\\.053566005491166725\ \(0\)\
\-\ well\\:\\ 0\\.05355587255715367\ \(0\)\
\-\ steroid\\:\\ 0\\.05330396681768709\ \(0\)\
\-\ lesion\\:\\ 0\\.05302687998200498\ \(0\)\
\-\ treatment\\:\\ 0\\.05268741044408187\ \(0\)\
\-\ dominant\\:\\ 0\\.05175425912390567\ \(0\)\
\-\ determine\\:\\ 0\\.0514292619643264\ \(0\)\
\-\ analysis\\:\\ 0\\.0514292619643264\ \(0\)\
\-\ serial\\:\\ 0\\.050910697683788864\ \(0\)\
\-\ observed\\:\\ 0\\.049244636816429266\ \(0\)\
\-\ disorders\\:\\ 0\\.048828485345307336\ \(0\)\
\-\ enhances\\:\\ 0\\.048747356497706645\ \(0\)\
\-\ therefore\\:\\ 0\\.048747356497706645\ \(0\)\
\-\ decrease\\:\\ 0\\.047533919763652774\ \(0\)\
\-\ difficulty\\:\\ 0\\.04651959752835747\ \(0\)\
\-\ medications\\:\\ 0\\.0463920319942928\ \(0\)\
\-\ until\\:\\ 0\\.04601910752885306\ \(0\)\
\-\ clinically\\:\\ 0\\.04595832462935529\ \(0\)\
\-\ difficult\\:\\ 0\\.04589792044196963\ \(0\)\
\-\ neurological\\:\\ 0\\.0454277754438435\ \(0\)\
\-\ infectious\\:\\ 0\\.04449854475072514\ \(0\)\
\-\ oral\\:\\ 0\\.04429226376199571\ \(0\)\
\-\ arm\\:\\ 0\\.044140383255570445\ \(0\)\
\-\ done\\:\\ 0\\.04399084547268397\ \(0\)\
\-\ csf\\:\\ 0\\.04369851657061185\ \(0\)\
\-\ not\\:\\ 0\\.04366453795248759\ \(0\)\
\-\ initially\\:\\ 0\\.0433682467504834\ \(0\)\
\-\ made\\:\\ 0\\.042653095673913115\ \(0\)\
\-\ symptomatic\\:\\ 0\\.0425246853103666\ \(0\)\
\-\ matter\\:\\ 0\\.04210853383924467\ \(0\)\
\-\ 24\\:\\ 0\\.03920812398576406\ \(0\)\
\-\ effect\\:\\ 0\\.038794256968341455\ \(0\)\
\-\ being\\:\\ 0\\.038537235829033054\ \(0\)\
\-\ cerebral\\:\\ 0\\.03831435611178033\ \(0\)\
\-\ presentation\\:\\ 0\\.03806959257465566\ \(0\)\
\-\ initial\\:\\ 0\\.0370992993859585\ \(0\)\
\-\ central\\:\\ 0\\.03693068921064874\ \(0\)\
\-\ surrounding\\:\\ 0\\.03688304861987879\ \(0\)\
\-\ white\\:\\ 0\\.03648728588542568\ \(0\)\
\-\ further\\:\\ 0\\.03601970582069996\ \(0\)\
\-\ area\\:\\ 0\\.03582601776611885\ \(0\)\
\-\ found\\:\\ 0\\.035783496466758144\ \(0\)\
\-\ any\\:\\ 0\\.03574116085051882\ \(0\)\
\-\ onset\\:\\ 0\\.03551156293421593\ \(0\)\
\-\ some\\:\\ 0\\.03479604515665789\ \(0\)\
\-\ yo\\:\\ 0\\.03455011405877877\ \(0\)\
\-\ t1\\:\\ 0\\.03445716185379346\ \(0\)\
\-\ treated\\:\\ 0\\.034438677881153665\ \(0\)\
\-\ evaluation\\:\\ 0\\.03372681026956977\ \(0\)\
\-\ for\\:\\ 0\\.03352376846219229\ \(0\)\
\-\ when\\:\\ 0\\.03340615097297873\ \(0\)\
\-\ on\\:\\ 0\\.03340484946676657\ \(0\)\
\-\ likely\\:\\ 0\\.033047645426837864\ \(0\)\
\-\ however\\:\\ 0\\.03273285021608077\ \(0\)\
\-\ signal\\:\\ 0\\.03134964106859299\ \(0\)\
\-\ man\\:\\ 0\\.029278041336439634\ \(0\)\
\-\ without\\:\\ 0\\.02917019994958932\ \(0\)\
\-\ imaging\\:\\ 0\\.029063544960695475\ \(0\)\
\-\ can\\:\\ 0\\.029021209344456157\ \(0\)\
\-\ most\\:\\ 0\\.028781303249922348\ \(0\)\
\-\ exam\\:\\ 0\\.027839506978222968\ \(0\)\
\-\ case\\:\\ 0\\.02778357504974285\ \(0\)\
\-\ multiple\\:\\ 0\\.02704985147570557\ \(0\)\
\-\ contrast\\:\\ 0\\.02687054944299803\ \(0\)\
\-\ seen\\:\\ 0\\.026036157035558175\ \(0\)\
\-\ also\\:\\ 0\\.026012898710018106\ \(0\)\
\-\ which\\:\\ 0\\.0251467783776332\ \(0\)\
\-\ by\\:\\ 0\\.02348481830623719\ \(0\)\
\-\ from\\:\\ 0\\.02196396685228666\ \(0\)\
\-\ an\\:\\ 0\\.021147642910578298\ \(0\)\
\-\ mass\\:\\ 0\\.021124231064588907\ \(0\)\
\-\ this\\:\\ 0\\.019003071993114184\ \(0\)\
\-\ left\\:\\ 0\\.01886502497860284\ \(0\)\
\-\ no\\:\\ 0\\.017983873452716282\ \(0\)\
\-\ is\\:\\ 0\\.015145074597970692\ \(0\)\
